Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Total Debt (2022 - 2025)

TriSalus Life Sciences' Total Debt history spans 4 years, with the latest figure at $33.0 million for Q4 2025.

  • For Q4 2025, Total Debt rose 49.64% year-over-year to $33.0 million; the TTM value through Dec 2025 reached $33.0 million, up 49.64%, while the annual FY2025 figure was $33.0 million, 49.64% up from the prior year.
  • Total Debt reached $33.0 million in Q4 2025 per TLSIW's latest filing, up from $32.8 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $33.0 million in Q4 2025 to a low of $4.7 million in Q1 2023.
  • Average Total Debt over 4 years is $22.5 million, with a median of $21.9 million recorded in 2024.
  • Peak YoY movement for Total Debt: surged 111.86% in 2024, then skyrocketed 49.64% in 2025.
  • A 4-year view of Total Debt shows it stood at $15.8 million in 2022, then plummeted by 36.49% to $10.0 million in 2023, then skyrocketed by 119.81% to $22.1 million in 2024, then surged by 49.64% to $33.0 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Total Debt are $33.0 million (Q4 2025), $32.8 million (Q3 2025), and $32.3 million (Q2 2025).